Evogene Completes Successful Sale of Lavie Bio to ICL Group, Expanding Agricultural Technologies

Evogene Completes Successful Sale of Lavie Bio to ICL Group



Evogene Ltd. (NASDAQ: EVGN) recently announced the successful closing of its significant transaction involving the sale of Lavie Bio Ltd., a subsidiary primarily engaged in ag-biologicals, to ICL Group Ltd. (NYSE: ICL). This strategic move marks a pivotal moment in Evogene's development, as it aims to enhance its focus on computational biology and artificial intelligence within the life sciences sector.

The announcement detailed the completion of the transaction, which was initially disclosed in April 2025. The deal encompasses the transfer of Lavie Bio’s core operations, including its proprietary Biology Driven Design (BDD) technology platform, its extensive microbial bank, various advanced development pipelines, and existing commercial products. As part of this transition, key personnel from Lavie Bio are set to join ICL, aligning resources with ICL’s broader agricultural initiatives.

CEO of Evogene, Ofer Haviv, expressed confidence that this transaction will propel advancements in the ag-biologicals field. He stated that combining Lavie Bio's innovative capabilities with ICL's robust global network and extensive operational prowess will bring forth more sustainable agricultural solutions. This strategic divestiture aligns closely with Evogene's overarching goal to unveil the inherent value within its subsidiaries and technologies.

Additionally, the agreement involves the divestiture of Evogene's MicroBoost AI, an advanced computational platform designed to bolster microbial product development in agriculture. However, it is noteworthy that Lavie Bio's existing commercial agreements and strategic partnerships will remain intact, preserving future revenue avenues for Lavie Bio’s stakeholders.

Dr. Elinor Erez, VP of R&D at ICL, reinforced the significance of this acquisition, highlighting ICL's commitment to leading the ag-biologicals sector. She noted that integrating Lavie Bio’s innovative platform with ICL's research and development expertise would enhance their biological solutions capabilities. This strategic acquisition not only strengthens ICL's position in the global marketplace but also reinforces their commitment to sustainable agricultural practices.

Evogene operates on the cutting edge of computational biology, leveraging AI and big data to expedite the development of life-science products. The company employs unique technological engines, including its MicroBoost AI, ChemPass AI, and GeneRator AI, each focused on various core components fundamental to life sciences. With a present focus on developing ag-chemicals, human microbiome therapeutics, and now ag-biologicals, Evogene continues to forge strategic partnerships that promote innovation within the industry.

The completion of the sale of Lavie Bio is a testament to Evogene's strategic vision and adaptability in a rapidly evolving marketplace. As local and global agricultural needs shift—such as the increasing demand for sustainable practices—Evogene's innovative developments and partnerships position it well for future success. This transition not only signifies a new chapter for Lavie Bio but also fires up expectations regarding forthcoming advancements in sustainable agricultural solutions.

In conclusion, as Evogene takes significant steps to align its business focus and fulfill its strategic objectives in computational biology, the sale of Lavie Bio to ICL is anticipated to enhance the delivery of innovative agricultural technologies. The journey ahead reveals strong potential as these organizations collaborate for the advancement of agricultural innovations, firmly grounded in sustainability and technological evolution.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.